RT Journal Article
SR Electronic
T1 Airborne Pathogen Detection in Fine Aerosol Exhaled Breath Condensates
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.05.25.22275435
DO 10.1101/2022.05.25.22275435
A1 Henderson, John
A1 Mantso, Theodora
A1 Ali, Saqib
A1 Groß, Rüdiger
A1 Müller, Janis A.
A1 Wilkinson, Amie
A1 Shah, Kavit
A1 Usher, Louise
A1 Auld, Beth
A1 Nelson, Andrew
A1 Cheung, William
A1 Namdeo, Anil
A1 Combrinck, Madeleine
A1 Hackney, Phil
A1 Turgul, Volkan
A1 Jahaj, Edison
A1 Athanasiou, Nikolaos
A1 Nikolouzakis, Taxiarchis
A1 Almeida, Pedro J.
A1 Rokka, Chrysa
A1 Queiroz, Daniel C.
A1 Wright, Edward
A1 Zafiropoulos, Alexandros
A1 Kale, Izzet
A1 Smith, Darren
A1 Kofteridis, Diamantis P.
A1 Tsatsakis, Aristides
A1 Münch, Jan
A1 Katsaounou, Paraskevi A.
A1 Kotanidou, Anastasia
A1 Lagiou, Pagona
A1 Magiorkinis, Gkikas
A1 Aquiar, Renato S
A1 Teixeira, Mauro M.
A1 Moschos, Sterghios A.
YR 2022
UL http://medrxiv.org/content/early/2022/09/05/2022.05.25.22275435.abstract
AB Rationale Exhaled breath condensate (EBC) promises a valuable, non-invasive, and easy to obtain clinical sample. However, it’s not currently used diagnostically due to poor reproducibility, sample contamination, and sample loss.Objective We evaluated whether a new, hand-held EBC collector (PBM-HALETM) that separates inertially impacted large droplets (LD) before condensing fine aerosols (FA) in distinct, self-sealing containers, overcomes current limitations.Methods Sampling consistency was determined in healthy volunteers by microbial culture, 16S phylogenetics, spectrophotometry, RT-PCR, and HILIC-MS. Capture of aerosolised polystyrene beads, liposomes, virus-like particles, or pseudotyped virus was analysed by nanoparticle tracking analysis, reporter expression assays, and flow cytometry. Acute symptomatic COVID-19 case tidal FA EBC viral load was quantified by RT-qPCR. Exhaled particles were counted by laser light scattering.Measurements and Main Results Salivary amylase-free FA EBC capture was linear (R2=0.9992; 0.25-30 min) yielding RNA (6.03 μg/mL) containing eukaryotic 18S rRNA (RT-qPCR; p<0.001) but not human GAPDH, RNase P, or beta actin mRNA;141 non-volatile metabolites included eukaryotic cell membrane components, and cuscohygrine 3 days after cocaine abuse. Culturable aerobe viability was condensation temperature-dependent. Breath fraction-specific microbiota were stable, identifying Streptococcus enrichment in a mild dry cough case. Nebulized pseudotyped virus infectivity loss <67% depended on condensation temperature, and particle charge-driven aggregation. SARS-CoV-2 RNA genomes were detected only by forced expiration FA EBC capture, in 100% of acute COVID-19 patients.Conclusions High purity, distal airway FA EBC can reproducibly and robustly inform contamination-free infectious agent emission sources, and be quantitatively assayed for multiple host, microbial, and lifestyle biomarker classes.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis project was supported by the InnovateUK iCURE III project no. 43055, and the Northern Accelerator II project no. 25R18P02557. JAM received funding from the German Research Foundation. Airborne particle size analysis was enabled by the kind loan of equipment by Particles Plus Inc.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All healthy volunteer EBC samples used within this study were obtained with participant informed consent under Northumbria University ethics application no. 43341 approved by the Department of Applied Sciences Subcommittee of University Research Ethics Committee. All COVID-19 patient EBC samples were collected under informed consent under the National and Kapodistrian University of Athens General Hospital Evangelismos ethics application protocol no. 280/24-4-2020 approved by the Scientific Committee of the General Hospital Evangelismos, and approval no. 54358021.1.0000.5149 fy the Institutional Review Board of the Federal University of Minas GeraisI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors